respiratory

R&D

May and June delivered a plethora of clinical trial updates. In the build-up to ASCO in June, our inbox was overflowing with oncology trial results.

News

Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.

News

AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.

Sales & Marketing

Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.

News

UK biotech Infex is in hot pursuit of Insmed's Brinsupri, the only approved therapy for non-CF bronchiectasis, with its quarterly-dosed antibody.

News

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in COPD, setting up filings.